Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has been assigned a consensus rating of “Buy” from the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $18.63.

A number of research analysts have weighed in on TRVI shares. HC Wainwright initiated coverage on shares of Trevi Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $21.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $24.00 price objective on shares of Trevi Therapeutics in a research note on Tuesday, May 20th. B. Riley reissued a “buy” rating and issued a $20.00 target price (up from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $9.00 to $29.00 in a research note on Monday, March 10th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research report on Wednesday, March 19th.

Insider Transactions at Trevi Therapeutics

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares of the company’s stock, valued at $519,075. The trade was a 51.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jennifer L. Good sold 5,263 shares of the company’s stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the sale, the chief executive officer now owns 213,313 shares in the company, valued at approximately $1,403,599.54. This represents a 2.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 18.30% of the company’s stock.

Hedge Funds Weigh In On Trevi Therapeutics

A number of large investors have recently modified their holdings of TRVI. China Universal Asset Management Co. Ltd. increased its holdings in Trevi Therapeutics by 10.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,925 shares of the company’s stock worth $113,000 after acquiring an additional 1,627 shares during the period. American Century Companies Inc. grew its position in shares of Trevi Therapeutics by 2.1% during the 1st quarter. American Century Companies Inc. now owns 79,796 shares of the company’s stock valued at $502,000 after purchasing an additional 1,653 shares in the last quarter. Summit Investment Advisors Inc. grew its position in shares of Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after purchasing an additional 2,894 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Trevi Therapeutics by 2.1% in the fourth quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company’s stock worth $578,000 after purchasing an additional 2,935 shares during the period. Finally, SG Americas Securities LLC raised its position in shares of Trevi Therapeutics by 14.5% in the fourth quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock worth $110,000 after buying an additional 3,387 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Price Performance

Shares of NASDAQ:TRVI opened at $6.50 on Friday. Trevi Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.39. The company has a market capitalization of $649.30 million, a PE ratio of -14.77 and a beta of 0.62. The business has a fifty day moving average price of $6.24 and a two-hundred day moving average price of $4.87.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.04. Sell-side analysts anticipate that Trevi Therapeutics will post -0.49 earnings per share for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.